| P2093 | author name string | Petros Grivas | |
| | Athanasios Papatsoris | |
| | Vadim S Koshkin | |
| | Moshe C Ornstein | |
| | Dharmesh Gopalakrishnan | |
| P2860 | cites work | Clonality of tumor-infiltrating lymphocytes in human urinary bladder carcinoma | Q73966320 |
| | Nivolumab Gets FDA Nod for Bladder Cancer | Q89244598 |
| | Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production | Q24292957 |
| | Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities | Q26775383 |
| | CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | Q26777563 |
| | Pembrolizumab | Q26796435 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | The role of the CD28 receptor during T cell responses to antigen | Q28263234 |
| | Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 |
| | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 |
| | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 |
| | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 |
| | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 |
| | Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 |
| | Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 |
| | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Q30251438 |
| | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Q30275266 |
| | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 |
| | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper | Q31034415 |
| | Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 | Q33398722 |
| | Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. | Q33399928 |
| | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Q33435967 |
| | Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification | Q33628683 |
| | FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy | Q33793541 |
| | Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial | Q34058870 |
| | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 |
| | CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics | Q34738334 |
| | The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 |
| | Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract | Q34997941 |
| | High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability | Q35787046 |
| | Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity | Q42204050 |
| | Durvalumab: First Global Approval | Q42374913 |
| | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer | Q42516513 |
| | Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis | Q44776446 |
| | Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 |
| | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial | Q47264823 |
| | Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis | Q47440377 |
| | Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon? | Q48413956 |
| | Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study | Q49821320 |
| | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q50205173 |
| | Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. | Q51532051 |
| | Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. | Q53103002 |
| | Neurological immune-related adverse events of ipilimumab | Q56897418 |
| | Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient | Q56898955 |
| | CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression | Q56905906 |
| | Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma | Q60682608 |
| | Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy | Q35965389 |
| | Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution | Q36069247 |
| | Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. | Q36383913 |
| | Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells | Q36539682 |
| | Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. | Q36863349 |
| | Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer | Q36900726 |
| | A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses | Q37010668 |
| | Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting | Q37053995 |
| | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Q37173548 |
| | Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting | Q37418530 |
| | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy | Q37629874 |
| | Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma | Q37641262 |
| | Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab | Q37809151 |
| | Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. | Q37935254 |
| | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. | Q38372019 |
| | Nivolumab: targeting PD-1 to bolster antitumor immunity | Q38387311 |
| | Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights | Q38549542 |
| | Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer | Q38663576 |
| | Immune-related adverse events with immune checkpoint blockade: a comprehensive review | Q38696141 |
| | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | Q38709131 |
| | Microsatellite Instability as a Biomarker for PD-1 Blockade | Q38735093 |
| | Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial | Q38735563 |
| | Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers | Q38796338 |
| | Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study | Q38855950 |
| | Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management | Q38925832 |
| | Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 |
| | Cancer Statistics, 2017. | Q39038674 |
| | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study | Q39084242 |
| | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Q39107888 |
| | Cutaneous adverse effects of the immune checkpoint inhibitors | Q39132344 |
| | Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy | Q39287502 |
| | Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 |
| | Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | Q40534742 |
| | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer | Q40715310 |
| | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. | Q41979947 |
| | Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer | Q42176800 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1019-1040 | |
| P577 | publication date | 2018-06-05 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. | |
| P478 | volume | 14 | |